Biofusion proteins as antimalarial vaccines
Patent Information
- Application Number
- JP2022085159
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2016-07-21
- Filing Date
- 2022-05-25
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2037-07-21
Smart Images

Figure 0007579298000011 
Figure 0007579298000012 
Figure 0007579298000013
Abstract
Description
[Technical field]
[0001] The present invention relates to protection against malaria, and more particularly to malaria vaccines comprising fusion proteins. [Background technology]
[0002] 2. Background of the Invention The parasites responsible for malaria in humans, including in particular Plasmodium falciparum, exhibit different morphologies in the human host and express different antigens depending on their localization in the organism of the infected host. The morphological and antigenic differences of these parasites in their life cycle in humans allow at least four distinguishable developmental stages. The very early developmental stage of the parasite in humans corresponds to the sporozoite form that is introduced into the host's blood by the bite of the parasite's insect vector. The second stage corresponds to the passage of the parasite to the liver and the infection of hepatocytes, in which the parasite develops to form liver schizonts that, when mature (for example, in the case of P. falciparum, on the sixth day after penetration of the sporozoites), release liver merozoites by rupture. The third stage is characterized by the infection of erythrocytes by asexual forms (blood stage schizonts) of the parasite, which, as they mature, release free merozoites; the development of this erythrocyte stage corresponds to the pathogenic phase of the disease. The fourth stage corresponds to the formation of reproductive forms (or gametocytes), which will become the extracellular reproductive forms or gametes in the mosquito.
[0003] There are no practical or effective vaccines introduced into clinical practice.
[0004] So far, malaria subunit vaccines have shown a massive lack of immunogenicity. The immune responses observed are low titer and short-lived. To address this lack, different approaches have been validated, including the choice of adjuvants, expression in complex vectors, e.g. virus-like particles (VLPs), adenoviral vectors, and the establishment of complex prime-boost protocols. Even the RTS,S / AS01 vaccine (Mosquirix®), engineered using repeats and T cell epitopes of the circumeryrocytic sporozoite protein (CSP) of the malaria parasite Plasmodium falciparum and genes from the viral envelope protein of the hepatitis B virus (HBsAg), together with high-performance adjuvants such as ASO1, suffers from a very short-lived malaria-specific immune response (whereas the hepatitis B response is long-lasting and high).
[0005] Chemical conjugation of Plasmodium antigens to carrier proteins has also been disclosed. For example, a vaccine containing the Plasmodium protein Pfs25H conjugated to a detoxified form of Pseudomonas aeruginosa exoprotein A (repA) is under evaluation.
[0006] However, chemical conjugation has several drawbacks: it is technically demanding, rarely reproducible and extremely expensive.
[0007] There remains a great need for vaccine products that are easily reproducible and inexpensive, yet exhibit good immunogenicity and protection against malaria. Summary of the Invention
[0008] The present invention offers the advantage of improved immunogenicity through novel constructs consisting of Plasmodium polypeptides fused to a carrier protein such as CRM197. Rather than chemically coupling the Plasmodium molecule to a carrier protein, the inventors have developed a novel approach to encode the parasite protein together with the carrier protein as a fusion protein to create a "bioconjugate fusion product" (further referred to herein as a "biofusion molecule") that can be recombinantly produced, for example, in E. coli.
[0009] More specifically, the present invention provides a fusion protein comprising at least one antigenic amino acid sequence fused to the N-terminus and / or C-terminus of a carrier heterologous protein sequence, wherein the antigenic sequence comprises an epitope sequence of a Plasmodium protein, and the carrier heterologous protein sequence is a sequence that is immunogenic in humans.
[0010] The antigenic sequence may be an antigenic protein or an epitope fragment thereof expressed by Plasmodium at the erythrocytic stage.
[0011] Alternatively, the antigenic sequence may be an antigenic protein, or an epitopic fragment thereof, expressed by Plasmodium at the pre-erythrocytic stage.
[0012] A further object of the present invention is a nucleic acid construct encoding a fusion protein as defined herein.
[0013] Vectors containing the nucleic acid constructs in expression cassettes, and host cells into which the vectors have been inserted, are also provided.
[0014] Further described is an in vitro method for preparing a fusion protein, which comprises allowing a host cell to replicate under conditions that induce expression of a nucleic acid construct, and harvesting the fusion protein thus expressed.
[0015] According to the present invention there is provided a vaccine comprising said fusion protein, or a combination of at least two fusion proteins each comprising at least two different antigenic amino acid sequences, or a nucleic acid construct encoding said fusion protein, together with a physiologically acceptable vehicle.
[0016] Such a vaccine is useful in vaccinating human subjects against malaria. [Brief description of the drawings]
[0017] [Figure 1] Figure 1 is a diagram of the coding sequence of PP21 (also referred to as "biofusion MSP3-1"). The base pair scale is shown below, starting from the NcoI site. [Diagram 2] FIG. 2 shows the pET26a-PP21 plasmid map (A), minipreparation analysis by restriction enzyme digestion with SmaI (B) or EcoRI (C). [Diagram 3] Recombinant protein PP21 purified by IMAC. (A) Analysis by electrophoresis under denaturing conditions and Coomassie blue staining. (B) Antigenicity assessed by Western blotting with mouse anti-MSP3 immune serum at a dilution of 1:1000. The upper band observed is consistent with the theoretical molecular weight of full-length PP21 of 84 kDa. An additional band at 37 kDa, which was poorly recognized by anti-MSP3 immune serum, may correspond to a degradation fragment of PP21. [Figure 4] Timescale of PP21 stability at different storage temperatures assessed by Western blotting with anti-MSP3-1 mAb RAM1 at a dilution of 1:1000. [Diagram 5]Determination of the antigen content of PP21 compared to the positive control MSP3-LSP. The antigenicity of preclinical PP21 was determined by its reactivity with a large panel of human and animal anti-MSP3 sera, including human recombinant antibodies. The antigen content provides a more accurate measure of the amount of reactive epitopes. It is performed by serial dilutions of the antigen, used for coating in an Elisa assay, and revealed by a well-defined positive control (here a pool of rats immunized with the C-terminal region of MSP3). The reactivity of PP21 was identical to that of MSP3 synthetic and recombinant constructs. [Figure 6] Significant improvement of specific antibody responses induced in mice after two immunizations with biofusion MSP3-1 conjugates compared to current MSP3-1-LSP. Groups of 5 (BALB / c) or 4 (C57BL / 6) mice were immunized with either 1 μg biofusion MSP3-1 alone or 10 μg MSP3-1 LSP in Montanide ISA720 on days 0, 14, and 28. Blood samples were collected one week after the second injection (day 21) (A) and one week after the third immunization (day 35). Specific MSP3-1 LSP antibody titers were determined by ELISA. Results for each mouse (1-5) are shown separately (here after only two immunizations). [Figure 7] Comparison of antibody responses induced in mice after two versus three immunizations with biofusion MSP3-1 compared to current MSP3-1-LSP. The third injection boosted the antibody response, confirming the superior immunogenicity of biofusion MSP3-1 in C57Bl / 6 and Balb / c mice. The mean titers of MSP3-1-LSP-specific antibodies induced by three injections of 1 μg of biofusion MSP3-1 reached 3×105 and 2×105 in C57Bl / 6 and Balb / c, respectively, whereas three injections of 10 μg of MSP3-1-LSP induced a maximum mean titer of 105 and 2.5×104 in C57Bl / 6 and Balb / c mice, respectively. [Figure 8-1]Significant improvement in the duration of MSP3-1 specific antibodies induced in mice by biofusion MSP3-1 compared to the current MSP3-1-LSP. A and B: Biofusion MSP3-CRM vs. MSP3-1-LSP: BALB / c (A-top left panel) and C57BL / 6 (B-top right panel) mice were immunized with either biofusion MSP3-1 1 μg alone or MSP3-1 LSP 10 μg in Montanide ISA720 on days 0, 14 and 28. Blood samples were collected on different days throughout the follow-up. Specific MSP3-1 LSP antibody titers were determined by ELISA. The results shown correspond to the geometric mean of anti-MSP3-1 LSP antibody titers obtained in each group of mice on different days. After 160 days of follow-up, the mean antibody titers in bio-fusion MSP3-1 conjugate immunized mice were 1.5×105 and 105 in C57bl / 6 and Balb / c, respectively, which is at least 10-fold higher than the mean titers of antibodies induced by MSP3-1-LSP, measured 160 days after the first immunization. C and D: Long-term persistence of immune responses elicited by MSP3-CRM: Groups of Balb / c and C57Bl6 mice (4-5 mice / group) were immunized by subcutaneous injection of 1 μg of bio-fusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v) on days 0, 14, and 103. Blood samples were collected on different days. Specific MSP3 antibody titers were determined by ELISA. The results show that, whereas titers increased significantly after two immunizations, reaching a maximum on day 49, a third antigen injection performed on day 103 did not induce any detectable increase in the magnitude of the antibody response. These specific antibodies only slightly decreased over time but were still detectable at high titers even 540 days after immunization. E: Long-term persistence of the immune response induced by MSP3-CRM after only two immunizations.Given the sufficient response observed after only two immunizations, this immunization scheme was analyzed in 17 additional Balb / c mice immunized by subcutaneous injection only on days 0 and 14 with 2 μg of biofusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v). Blood samples were collected on different days. Specific MSP3-1-LSP antibody titers were determined by ELISA. The results show that MSP3 antibody titers increased after two antigen injections, reaching a maximum between days 42 and 72 in all mice, indicating a negligible decrease in the immune response over the entire 380-day follow-up of the experiment. [Figure 8-2]Significant improvement in the duration of MSP3-1 specific antibodies induced in mice by biofusion MSP3-1 compared to the current MSP3-1-LSP. A and B: Biofusion MSP3-CRM vs. MSP3-1-LSP: BALB / c (A-top left panel) and C57BL / 6 (B-top right panel) mice were immunized with either biofusion MSP3-1 1 μg alone or MSP3-1 LSP 10 μg in Montanide ISA720 on days 0, 14 and 28. Blood samples were collected on different days throughout the follow-up. Specific MSP3-1 LSP antibody titers were determined by ELISA. The results shown correspond to the geometric mean of anti-MSP3-1 LSP antibody titers obtained in each group of mice on different days. After 160 days of follow-up, the mean antibody titers in bio-fusion MSP3-1 conjugate immunized mice were 1.5×105 and 105 in C57bl / 6 and Balb / c, respectively, which is at least 10-fold higher than the mean titers of antibodies induced by MSP3-1-LSP, measured 160 days after the first immunization. C and D: Long-term persistence of immune responses elicited by MSP3-CRM: Groups of Balb / c and C57Bl6 mice (4-5 mice / group) were immunized by subcutaneous injection of 1 μg of bio-fusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v) on days 0, 14, and 103. Blood samples were collected on different days. Specific MSP3 antibody titers were determined by ELISA. The results show that, whereas titers increased significantly after two immunizations, reaching a maximum on day 49, a third antigen injection performed on day 103 did not induce any detectable increase in the magnitude of the antibody response. These specific antibodies only slightly decreased over time but were still detectable at high titers even 540 days after immunization. E: Long-term persistence of the immune response induced by MSP3-CRM after only two immunizations.Given the sufficient response observed after only two immunizations, this immunization scheme was analyzed in 17 additional Balb / c mice immunized by subcutaneous injection only on days 0 and 14 with 2 μg of biofusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v). Blood samples were collected on different days. Specific MSP3-1-LSP antibody titers were determined by ELISA. The results show that MSP3 antibody titers increased after two antigen injections, reaching a maximum between days 42 and 72 in all mice, indicating a negligible decrease in the immune response over the entire 380-day follow-up of the experiment. [Figure 8-3]Significant improvement in the duration of MSP3-1 specific antibodies induced in mice by biofusion MSP3-1 compared to the current MSP3-1-LSP. A and B: Biofusion MSP3-CRM vs. MSP3-1-LSP: BALB / c (A-top left panel) and C57BL / 6 (B-top right panel) mice were immunized with either biofusion MSP3-1 1 μg alone or MSP3-1 LSP 10 μg in Montanide ISA720 on days 0, 14 and 28. Blood samples were collected on different days throughout the follow-up. Specific MSP3-1 LSP antibody titers were determined by ELISA. The results shown correspond to the geometric mean of anti-MSP3-1 LSP antibody titers obtained in each group of mice on different days. After 160 days of follow-up, the mean antibody titers in bio-fusion MSP3-1 conjugate immunized mice were 1.5×105 and 105 in C57bl / 6 and Balb / c, respectively, which is at least 10-fold higher than the mean titers of antibodies induced by MSP3-1-LSP, measured 160 days after the first immunization. C and D: Long-term persistence of immune responses elicited by MSP3-CRM: Groups of Balb / c and C57Bl6 mice (4-5 mice / group) were immunized by subcutaneous injection of 1 μg of bio-fusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v) on days 0, 14, and 103. Blood samples were collected on different days. Specific MSP3 antibody titers were determined by ELISA. The results show that, whereas titers increased significantly after two immunizations, reaching a maximum on day 49, a third antigen injection performed on day 103 did not induce any detectable increase in the magnitude of the antibody response. These specific antibodies only slightly decreased over time but were still detectable at high titers even 540 days after immunization. E: Long-term persistence of the immune response induced by MSP3-CRM after only two immunizations.Given the sufficient response observed after only two immunizations, this immunization scheme was analyzed in 17 additional Balb / c mice immunized by subcutaneous injection only on days 0 and 14 with 2 μg of biofusion MSP3-CRM adjuvanted with Montanide ISA 720 adjuvant (v / v). Blood samples were collected on different days. Specific MSP3-1-LSP antibody titers were determined by ELISA. The results show that MSP3 antibody titers increased after two antigen injections, reaching a maximum between days 42 and 72 in all mice, indicating a negligible decrease in the immune response over the entire 380-day follow-up of the experiment. [Figure 9] Improved recognition of MSP3-1 ADCI (Ab-dependent cell inhibition) target epitopes by antibodies induced in mice immunized with biofusion MSP3-1 compared to MSP3-1-LSP. In MSP3-1-LSP, peptides "b", "c" and "d" define distinct B cell epitopes targeted by antibodies effective in ADCI assays that correlate with the protective effect of anti-MSP3-1 antibodies. To evaluate the ability of biofusion MSP3-1 to induce antibodies against these epitopes, we determined the titers of antibodies against peptides a, b, c and d in serum by ELISA. Thus, the number of ADCI targets recognized by the new formulation is rather broad and the titers are higher. BALB / c and C57BL / 6 mice were immunized on days 0, 14 and 28 with either only 1 μg biofusion MSP3-1 or 10 μg MSP3-1 LSP in Montanide ISA720. One week after the third immunization (day 35), blood samples were collected. Mouse sera were diluted 1 / 400 and the specific antibody titers of the different MSP3-1 peptides (a, b, c and d) were determined by ELISA. The results shown correspond to the optical density obtained with each mouse serum tested. [Figure 10]Human antibody responses in HIMM model (human immunogenic mouse model) immunized with either 1 μg biofusion MSP3-1, 10 μg current MSP3-1 LSP or 10 μg MSP3-1 C-terminal recombinant protein. Human splenocytes stimulated or not stimulated in vitro with 1 μg / ml antigen were transplanted into NOD.Cg-Prkdcscid-IL2rgtm1WjI / SzJ (NSG) mice (4 mice / group). Each NSG mouse received an intraperitoneal injection (ip) of 30×106 antigen primed or non-primed splenocytes. On days 7 and 21, reconstituted mice were boosted with 1 μg biofusion MSP3-1, 10 μg MSP3-1-LSP or 10 μg MSP3-1 C-terminal recombinant protein. All antigens were adjuvanted with Montanide ISA 720 (v / v) and injected intraperitoneally (ip). Mice reconstituted with non-primed splenocytes received adjuvant alone. Blood samples were collected one week after each immunization. Specific antibodies were analyzed by total IgG ELISA and specific IgG ELISA. Adjusted specific antibody titers were calculated using the following formula: (antigen-specific antibody titer / total human IgG concentration) x 10 (considering 10 mg / ml as the mean human total IgG concentration). Geometric mean ELISA titers (95% CI) are presented. [Figure 11] Human IFN-γ cellular responses in HIMM model (Hu lymphoid NSG mice) immunized with either 1 μg biofusion MSP3-1, 10 μg current MSP3-1 LSP or 10 μg MSP3-1 C-terminal recombinant protein. Same immunization conditions as above. Cellular responses were evaluated by IFN-γ ELISPOT. On day 28, spleen cells from each group of mice were harvested, pooled and cultured in vitro with or without antigen stimulation. The results shown correspond to the specific spot-forming cells (SFC) obtained with each group of mice. [Figure 12] T cell responses in HIMM: Significant improvement of CD4-Th1 responses in human lymphocytes transferred into mice immunized with either 1 μg bioconjugate PP21 or 10 μg MSP3-LSP. [Figure 13] Improved recognition of parasite native proteins by human antibodies elicited in a HIMM model immunized with biofusion MSP3-1. Human splenocytes were transplanted into NSG mice and immunized with either 1 μg biofusion MSP3-1, 10 μg current MSP3-1 LSP or 10 μg MSP3-1 C-terminal recombinant protein (as described in Figure 6). Reactivity of human antibodies with parasite proteins in mouse serum at day 28 (which is a key feature for activating ADCI defense mechanisms during a malarial attack) was evaluated by immunofluorescence antibody test (IFAT) against 3D7 Plasmodium falciparum (Pf)-infected erythrocytes. The results shown correspond to the range of titers obtained with each group of mice. [Figure 14] The human antibody response elicited in the HIMM model immunized with 1 μg of biofusion MSP3-1 is independent of the adjuvant used for the vaccine preparation. (A) Human spleen cells from two different donors stimulated or not stimulated with 1 μg of biofusion MSP3-1 adjuvanted with Montanide ISA 720 (as described in Figure 6) were transplanted into NSG mice (4 mice / group / donor). (B) Human spleen cells stimulated or not stimulated with 1 μg of biofusion MSP3-1 adjuvanted with MF59 instead of Montanide ISA 720 (9 mice) (8 mice) were transplanted into NSG mice (as described in Figure 6 but for human lymphocytes from distinct donors). In both cases, specific MSP3-1 LSP antibody titers were determined by ELISA on day 28. The results shown correspond to the mean ± SD of the ELISA titers obtained with each group of mice. [Figure 15]Antibody subclasses of human IgG antibodies elicited in human lymphocytes in a HIMM model immunized with biofusion MSP3-1 adjuvanted with Montanide ISA 720. Human splenocytes stimulated or not with 1 μg MSP3 biofusion (as described in FIG. 10) were transplanted into NSG mice. Mouse sera collected on day 28 were diluted 1 / 20. Specific MSP3-1 LSP antibody titers were determined by subclass IgG ELISA. Results shown correspond to the mean ± SD of optical density obtained with immunized and non-immunized mice. [Figure 16] Human IgG antibody subclasses induced in a HIMM model immunized with biofusion MSP3-1 adjuvanted with MF59. NSG mice were transplanted with human splenocytes stimulated or not with 1 μg of biofusion MSP3-1 adjuvanted with MF59 (as described in FIG. 14). Mouse sera collected on day 28 were diluted 1 / 20. Specific MSP3-1 LSP antibody titers were determined by subclass IgG ELISA in serum of responding mice. Results shown correspond to the mean ± SD of optical densities obtained with immunized and non-immunized mice. Both adjuvants established the dominance of the cytotropic subclass IgG1. [Figure 17] Immunogenicity of 0.2 or 1 μg of PP21 / PP21-montanide in Balbc mice (top left and top right panels) or the same dose in C57bl mice (bottom left and bottom right panels). Time course of anti-MSP3-1-LSP antibody titers determined as in Figures 6-8. [Figure 18] Cross-reactivity of anti-MSP3-1 antibodies induced by PP21 with other MSP3 family member proteins (OD values by Elisa). C57Bl / 6 (C) and Balb / c (B) mice were administered two injections of 4 μg PP21 (J0, J14). Samples were collected on day 63. [Figure 19]Immunogenicity of PP21 adjuvanted with alum hydroxide in C57BL (C) and BALB / c mice (B) (dose 1 μg / immunization). Antibody titers determined by Elisa in C57BL (C) and Balb / C mice (B) after two or three immunizations are shown. Dilutions higher than 25:600 were not tested. In contrast, it should be noted that alum OH, which is a strong adjuvant in humans and results in high Th1 responses, is usually a poor adjuvant in rodents, but still induced a strong response with PP21. [Figure 20] High immunogenicity of the biofusion conjugate PP21 in South American Saimiri sciureus monkeys. Captive-born Saimiri sciureus South American monkeys in the animal house of the Primate Center of Belem, Brasil, were immunized subcutaneously with 1 μg of PP21 adjuvanted with Montanide Isa 720 (dotted line compared to a control that received only Montanide (flat line)) on days 0, 28 and 112. Antibodies were determined by Elisa against the MSP3-LSP antigen, as well as by IFAT and WB (not shown). Even when only 0.1 μg of antigen was used per immunization, the immune response was about 5-fold lower (i.e. still highly significant) (not shown). [Figure 21] Antibody responses elicited by LSA3-CRM(PP25) vs. LSA3-729 in Balb / C mice administered either 1 μg PP25 in Montanide ISA720 or 10 μg LSA3-729 in Montanide ISA720. Immunizations were performed on days 0, 7, and 28, and serum was collected on day 45. [Figure 22] IFNγ induced in LSA3-CRM(PP25) versus LSA3-729 immunized Balb / C mice challenged in vitro with DG729 (ELISPOT). [Figure 23]Reproducibility of anti-LSA3-729 human antibody responses in HIMM and improved outcomes: Anti-LSA3-729 human antibody responses to the LSA3-CRM construct PP25 in HIMM using lymphocytes from two human donors ≪A≫ and ≪B≫ [Figure 24] Improved duration of PP25-induced immune responses. [Diagram 25] A novel host cell for P. falciparum liver stage development in HuH7.5 was developed and compared with human primary hepatocytes (HPH). The figure shows representative samples of liver schizonts at 4, 5 and 7 days after sporozoite infection immunostained with mouse polyclonal anti-PfHsp-70. Magnification 400x, scale bar 10 μm. At day 7, it was difficult to find sufficient LS in HPH. We then used this hepatoma model in a functional assay to measure antibodies that could inhibit sporozoite invasion into hepatocytes. [Figure 26] Inhibition of sporozoite invasion in Hu7.5 hepatoma cells (ILSDA) by anti-PfLSA3 antibodies. Correlation between anti-LSA3 reactivity to native protein (by IFAT assay) and functional inhibitory effect in liver stage development inhibition assay (ILSDA) is shown. The smaller graph shows the same assay using anti-sporozoite periplasmic mAb 2A10. [Figure 27] In human lymphocytes transplanted in the HIMM model, strong B and T cell responses were elicited by the construct PP23 (MSP3-2-CRMP97-MSP3-3). The top panel (A) shows the antibody response, and the middle panel (B) shows the isotype distribution, which is dominated by the IgG1 class, the main cell affinity class that can act in concert with monocytes in the ADCI mechanism. The bottom panel (C) shows the T cell response assessed by IFN-γ secretion restimulated in vitro with either MSP3-2 or MSP3-3. [Figure 28]Immunogenicity of biofusion LSA5-CRM / Montanide ISA 720 dose 1 μg compared to 10 μg in BALb / c mice (n=5). Experimental conditions are similar to those described in FIG. 8. Immunization with biofusion LSA5-CRM / Montanide ISA 720 was performed on days 0, 14 and 28 (arrows). Serum antibody detection was performed by ELISA titration against LSA5-LSP as antigen using sera collected on days 0, 7, 21 and 42. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Detailed Description of the Invention definition "Vaccine" should be understood to mean a composition for generating immunity for the prevention and / or treatment of disease. Thus, a vaccine is a medicine that contains an antigen and is intended to be used in humans or animals to generate a specific defense and protection by vaccination. As used herein, "vaccine" means an immunogenic composition that can induce partial or complete protection against malaria. A vaccine can be prophylactic against infection and / or therapeutic in infected individuals.
[0019] The term "immunogenic" means that the composition or protein to which it refers is capable of inducing an immune response upon administration. An "immune response" in a subject refers to the development of an adaptive and / or innate immune response, including a humoral immune response, a cellular immune response, or a humoral and cellular immune response, to an antigen. A "humoral immune response" refers to one that is mediated by antibodies.
[0020] As used in this document, the term "protection" or "prevention" refers to the absence of symptoms or the presence of reduced symptoms of disease following contact with Plasmodium parasites. In particular, the term "prevention of malaria" refers to the absence of symptoms or the presence of reduced symptoms in a treated subject following contact with Plasmodium, which causes malaria.
[0021] A "patient" or "subject" is typically a mammalian subject, preferably a human subject. The subject may be male or female, child or adult. The subject may be one that has previously been diagnosed or identified as having malaria. Alternatively, the subject may also be one that has not previously been diagnosed as having malaria but is at risk of developing such a condition, for example, by infection or by travel in a malaria endemic area. For example, the subject may be one that exhibits one or more symptoms of malaria.
[0022] For example, the subject may be infected with Plasmodium falciparum or Plasmodium vivax.
[0023] A sequence that is "homologous" or "substantially homologous" to an original polypeptide is typically one that has at least about 80 percent identity with the sequence of the original polypeptide or an immunogenic or epitopic fragment of the original polypeptide, and that substantially retains the desired effect of the original polypeptide on its intended target (i.e., eliciting an immunogenic response or being recognized by an antibody). In more preferred embodiments, a homologous sequence has at least about 85 percent, 90 percent, 95 percent, 97 percent, or 99 percent identity with the sequence of the original polypeptide or an immunogenic or epitopic fragment thereof.
[0024] An "immunogenic fragment" generally has a length of at least 5 amino acids. More preferably, the length of an immunogenic fragment is at least 7, 9, 11, 13, 15, 17, and 19 amino acids. An "epitope" generally has a length of at least 5 amino acids, preferably at least 7-14 amino acids. An "epitope fragment" may be longer since it contains such an epitope.
[0025] In the context of the present invention, the term "fusion or biofusion" means that in a recombinant protein, a carrier protein is either directly linked to an antigenic Plasmodium sequence or linked to the antigenic Plasmodium sequence by a peptide linker. The peptide linker may be a sequence of 1 to 35 amino acids, preferably 5 to 20 amino acids, more preferably 5 to 10 amino acids. In a preferred embodiment, the linker peptide is (Gly-Gly-Gly-Gly-Ser) n , (Gly) n or (EAAAK) n (n is 1 to 4, preferably 1 to 3). In either embodiment, a single polypeptide is formed.
[0026] Carrier Proteins The carrier heterologous protein sequence may advantageously be selected from the group consisting of diphtheria toxoid cross-reacting material (CRM), diphtheria toxoid (D), non-toxic mutant recombinant Pseudomonas aeruginosa exoprotein A (repA), meningococcal outer membrane protein complex (OMPC), tetanus toxoid (T), H. influenza protein D (hiD) and immunogenic fragments thereof.
[0027] In a preferred embodiment, the carrier heterologous protein sequence may be CRM197 or an immunogenic fragment thereof, which fragment is preferably selected from the group consisting of fragment A, transmembrane domain T, receptor binding domain R of CRM197, amino acid sequence 1 to 190 of CRM197 and amino acid sequence 1 to 389 of CRM197.
[0028] Fragment A of diphtherin toxin spans amino acids 1 to 201. CRM197 has an enzymatically inactive fragment A and displays substitution of glycine 52 with glutamic acid.
[0029] Fragment B of diphtherin toxin spans amino acids 202-535.
[0030] [Table 1]
[0031] Substantially homologous sequences may also be used.
[0032] Antigenic Plasmodium sequences The fusion protein construct of the present invention comprises at least one antigenic sequence which comprises an epitope sequence of a Plasmodium protein.
[0033] The antigenic sequence can be of any Plasmodium antigen from any Plasmodium species.
[0034] The "Plasmodium" genus of parasites that infect humans includes, but is not limited to, P. falciparum, P. vivax, P. knowles, P. ovale, and P. malariae. The antigens listed below are primarily from P. falciparum. However, orthologs in other Plasmodium species are included as well. In particular, P. vivax antigens have shown the same low immunogenicity as P. falciparum antigens.
[0035] The antigens may be expressed at the erythrocytic stage (also referred to as "blood stage") or at the pre-erythrocytic stage (sporozoite and liver stages).
[0036] Examples of antigenic sequences that can be used are listed below in Table 2. Substantially homologous sequences can also be used.
[0037] Antigens expressed in the erythrocytic stage that are targets of the Ab-dependent cellular inhibition (ADCI) defense mechanism include MSP3 (e.g., MSP3-1, MSP3-2, MSP3-3, MSP3-4, MSP3-7, MSP3-8), the PEBS subregion of 11-1 (also called LSA5), Glurp R0 and R2, SERP, P27 and P27A, P45, P90 and P77, P14, P181 (which is a combination of P77), MSP1-Block 2, MSP2 (the two 3D7 and FC27 alleles, both the dimorphic and constant regions), GBP 130 (particularly both the N and C portions), protein 332, protein 11-1, MSP4, or any epitope fragments thereof.
[0038] Preferably, the antigenic sequence in the fusion protein is MSP3 or an epitopic fragment thereof.
[0039] In another preferred embodiment, the antigenic sequence in the fusion protein is LSA5 or an epitopic fragment thereof.
[0040] Plasmodium falciparum merozoite surface protein 3 (MSP-3) is a known asexual blood-stage malaria vaccine candidate antigen (Sirima et al, N Engl J Med 2011, 365(11):1062-1064; Demanga et al, Infect Immun 2010, 78(1):486-494; Daher et al, Infect Immun 2010, 78(1):477-485; Rousillon et al, Roussilhon, et al, PLoS Medicine, November 2007, 4, Issue 11, e320).
[0041] In particular, any of the six MSP3 proteins may be used, preferably MSP3-1, but also the full length and N-terminus of the protein as well as peptides a, b, c, d, e, f (recombinant C-terminus).In a preferred embodiment, the antigenic sequence is MSP3 or an epitopic fragment thereof, which fragment encompasses motifs a, b, c, d, e and / or f of the C-terminal region of Plasmodium MSP3 proteins selected from among MSP3-1, MSP3-2, MSP3-3, MSP3-4, MSP3-7, MSP3-8.
[0042] Other antigens from the merozoite surface are included, particularly those that are loosely attached or cleaved and therefore may be released from the merozoite surface.
[0043] Antigens expressed at the pre-erythrocytic stage include LSA3, PEBS, CS, Trap and Salsa and any epitope fragments thereof. In P. falciparum, liver stage antigen-3 (LSA-3) is an antigen expressed at the pre-erythrocytic stage (Toure-Balde et al: Infect Immun 2009, 77(3):1189-1196; Daubersies et al: Nat Med 2000, 6(11):1258-1263).
[0044] Antigens involved in other stages or mechanisms are also encompassed, including antigens involved in the sexual phase, such as Pf25 or Pf45 / 48, and blood stage antigens involved in the GIA mechanism of inhibition of merozoite invasion in erythrocytes, such as Rh5, AMA1, MSP1-19, MSP1-42, MSP2 or MSP4-5, or antigens involved in cell adhesion, such as Var CSA. [Table 2] TIFF0007579298000003.tif248168 TIFF0007579298000004.tif113168
[0045] fusion construct In a particular embodiment, the fusion protein comprises or consists of MSP3 (preferably MSP3-1), LSA3, LSA5 (also referred to as PEBS) or an epitopic fragment thereof as an antigenic sequence fused to CRM197 or an immunogenic fragment thereof as a carrier sequence.
[0046] In a preferred embodiment, the fusion protein comprises two antigenic sequences located at the C-terminus and N-terminus, respectively, of the carrier protein sequence, or both at the same terminus, and the two antigenic sequences are either the same or different from each other.
[0047] In a preferred embodiment, the fusion between the antigenic sequence and the carrier sequence is a direct fusion.
[0048] In another embodiment, the at least one amino acid sequence may be linked to the N-terminus and / or C-terminus of the carrier heterologous protein sequence by a peptide linker, which is preferably a sequence of 1 to 35 amino acids, preferably 5 to 20 amino acids. In a preferred embodiment, the peptide linker is (Gly-Gly-Gly-Gly-Ser) n , (Gly) n or (EAAAK) n (n is 1 to 4, preferably 1 to 3).
[0049] Nucleic Acids, Vectors and Host Cells The fusion protein of the invention can be produced by any recombinant technique. Therefore, another aspect of the invention relates to a vector, preferably an expression vector, containing a nucleic acid encoding said fusion protein.
[0050] The expression vectors used in the present invention may provide for expression in vitro and / or in vivo (e.g. in a suitable host cell, host organism and / or expression system). They typically comprise a polynucleotide sequence as defined above and regulatory sequences (e.g. suitable promoters, enhancers, terminators, etc.) that allow the expression (e.g. transcription and translation) of a protein product in a host cell or organism.
[0051] The vector of the present invention may be in the form of a vector, such as a plasmid, cosmid, YAC, viral vector or transposon.
[0052] In preferred, but non-limiting, embodiments, the vectors of the invention comprise i) at least one of the above-mentioned nucleic acids operably linked to ii) one or more regulatory elements, such as a promoter and optionally a suitable terminator; and optionally further iii) one or more further elements of the genetic construct, such as 3'- or 5'-UTR sequences, leader sequences, selection markers, expression markers / reporter genes, and / or elements that may facilitate or increase (the efficiency of) transformation or integration.
[0053] A preferred host cell is E. coli, however any prokaryotic or eukaryotic expression system can be used, including bacteria, yeast, filamentous fungi, insect, plant cells and mammalian cells.
[0054] Preferred vectors, promoters and host cells are all vectors, promoters and host cells which are capable of expressing glycosylated or non-glycosylated recombinant proteins, such as pET26a (containing the T7 promoter) or pTrcHis2 (containing the trp lac promoter) plasmids for prokaryotic expression, pUC19, pUC 57 or pCR4 TOPO plasmids for transfer and E. coli BL21(DE3) or E. coli NiCo21 host cells for protein expression, or E. coli Top 10 only for plasmid amplification.
[0055] Vaccine preparations The fusion protein, optionally in combination with an adjuvant, is formulated into a pharmaceutical composition in association with a physiologically acceptable vehicle.
[0056] Thus, there is provided a vaccine comprising a fusion protein or a combination of at least two fusion proteins, each containing at least two different antigenic amino acid sequences, together with a physiologically acceptable vehicle.
[0057] In another embodiment, a vaccine composition is provided comprising a nucleic acid construct encoding the fusion protein.
[0058] In some embodiments, the vaccine may include one or more pharma- ceutically acceptable vehicles or excipients. Excipients include any component that does not itself induce the production of antibodies and is not harmful to the subject to which the composition is administered. Suitable excipients are typically large slowly metabolized macromolecules such as sugars, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, sucrose, trehalose, lactose, and lipid aggregates (e.g., oil droplets or liposomes). Suitable pharmaceutical vehicles are well known to those skilled in the art and include, but are not limited to, diluents such as water, saline, and the like. Sterile pyrogen-free phosphate-buffered saline is a suitable pharmaceutical vehicle. In addition, additives such as wetting or emulsifying agents, pH buffering substances, and the like may be present.
[0059] The pharmaceutical composition, immunogenic composition or vaccine may further comprise an adjuvant. An "adjuvant" is used to enhance the effectiveness of the composition and includes, but is not limited to, aluminum hydroxide (alum), aluminum phosphate, oil-in-water or water-in-oil emulsions, agonists of Toll-like receptors, N-acetyl-normuramyl-L-alanyl-D-isoglutamine (the-MDP), N-acetyl-muramyl-L-threonyl-D-isoglutamine (nor-MDP), PEI; AS01 or AS02 (GlaxoSmithKline), GLA-SE (IDRI) and similar formulations; and similar adjuvants known in the art. Montanide® adjuvants, including ISA 51 and 720, which are based on purified squalene and squalane emulsified with highly purified mannide monooleate, may also be used. MF59® is another example of an adjuvant and is an oil-in-water emulsion of squalene, polyoxyethylene sorbitan monooleate (Tween® 80) and sorbitan trioleate.
[0060] The vaccine is formulated in a dosage appropriate for the subject to which it is to be administered. The dosage administered may vary depending on the individual's symptoms, sex, weight, and age; the route of administration; and the adjuvant used. The vaccine may be used in dosage forms such as a suspension or liquid solution. The vaccine may be formulated with a pharma- ceutically acceptable vehicle as described above. Suitable dosages include, but are not limited to, about 0.1 to about 100 micrograms, preferably about 1 to about 50 micrograms, more preferably 1 to 20, 1 to 15, or even 1 to 10 micrograms of the fusion protein described herein.
[0061] Vaccination The immunogenic composition or vaccine may be a multi-component / multi-antigen immunogenic composition or vaccine.
[0062] If the immunogenic composition or vaccine is intended for a multiple administration regime, such as a prime-boost regime, the prime composition may comprise the same or different composition as the boost composition, however, in the context of the present invention, a prime-boost regime is not required at all.
[0063] The immunogenic composition or vaccine may be administered by any convenient route, preferably parenterally, intramuscularly, intradermally, subcutaneously, mucosally or intravenously.
[0064] For DNA vaccination, various techniques are available such as electroporation, needle-free approaches such as particle bombardment and high pressure delivery, skin patches, formulation of DNA vaccines in microparticles or liposomes.
[0065] A method for eliciting an immune response in a subject is described, comprising administering an effective amount of the vaccine of the present invention. The vaccine can be administered prophylactically (i.e., to prevent infection) or to provide protection, preferably with the induction of antibody and / or T cell immunity. The method can elicit a primary immune response, a secondary immune response, a booster response, or a combination of immune responses.
[0066] A vaccine is meant to protect a subject against malaria at any stage, including the pre-erythrocytic stage, such as the liver stage, and / or the sexual or asexual blood stages.
[0067] According to the present invention, the magnitude and / or memory of the immune response to a Plasmodium antigen is increased.
[0068] In particular, the MSP3 fusion constructs of the invention trigger the production of anti-MSP3 cytotropic antibodies, such as IgG1 and IgG3 antibodies, and the level of protection can be determined by measuring the titer of said antibodies.
[0069] The figures and examples are illustrative of the invention and do not limit its scope. EXAMPLES
[0070] Previous studies have shown that frequent exposure to malaria leads to the development of immunity in adults that prevents or mitigates the disease, and this immunity can be passively transferred by administering immunoglobulin (IgG) from malaria-immune adults.
[0071] A parasite killing mechanism termed antibody-dependent cellular inhibition (ADCI) was identified. Screening of genome-wide DNA libraries with ADCI led to the identification of merozoite surface protein 3 (MSP3) and subsequently several other antigens, including PEBS.
[0072] Cytophilic antibodies have been identified as protective surrogates: the cytophilic (leukocyte-binding) anti-MSP3 antibodies IgG1 and IgG3 that mediate ADCI have been consistently found to be associated with reduced risk of malaria in epidemiological studies in many different settings. These antibodies also mediate protection against P. falciparum in infected animals.
[0073] These studies indicate the characteristics of an efficient immune response and lead to the development of improved vaccine formulations.
[0074] Based on this, we now show that the fusion protein CRM97-MSP3 increases immunogenicity by 20-100 fold at the B and T cell levels compared to MSP3-LSP (a long synthetic peptide covering the 186-271 region of MSP3-1), see Example 1. The use of a 10-fold lower immunization dose resulted in greatly improved immunogenicity against lymphocytes from humans, mice and squirrel monkeys, and greatly improved antibody duration.
[0075] At the pre-erythrocytic stage, previous studies have shown that LSA3 can induce a protective effect against extensive sporozoite challenge in chimpanzees, but this effect is further shown to be dependent on IFN-γ, which may inhibit LS development, and antibodies, which prevent sporozoite invasion.
[0076] In Example 2, the inventors demonstrated that the biofusion CRM-LSA3 construct strongly increased T and B cell responses.
[0077] The results obtained in Examples 1 and 2 proved to be reproducible using other antigens from the erythrocytic stage, such as MSP3-2 and MSP3-3, in constructs bearing CRM (see Example 3).
[0078] Example 4 provides results with the LSA5-CRM construct.
[0079] Materials and Methods Generation of expression constructs and production of biofusion proteins in Escherichia coli The gene sequence (Figure 1) encoding the chimeric immunogen composed of detoxified diphtheria toxin CRM197 covalently linked at both its N- and C-termini to a malaria peptide antigen was chemically synthesized (GenScript) and codon-optimized for production in E. coli. Restriction sites for NcoI and XhoI were added at the 5' and 3' ends, respectively, for cloning in the expression plasmid pET-26a (Novagen). The sequence inserted into the shuttle plasmid pUC57 was checked by sequencing and quickly lyophilized (4 μg).
[0080] The MSP3-1 peptide in PP21 (plasmodB acc.Nbr PF3D7_1035400) corresponds to amino acids (AA) 155 to 249 in MSP3-1.
[0081] Other hybrid immunogens (Table 3) have been designed around CRM197. In PP22, the MSP3-2 peptide (AA 178-257 of MSP3-2, PlasmodB acc.Nbr PF3D7_1035500) replaced the MSP3-1 peptide. In PP23, the MSP3-3 peptide (AA 246-307 of MSP3-3, PlasmodB acc.Nbr PF3D7_1035600) replaced the MSP3-2 peptide at the C-terminus. PP25 contains the same LSA3 peptide (AA 176-325, PlasmodB acc.Nbr PF3D7_0220000) at both CRM197 termini. [Table 3]
[0082] For cloning molecular procedures and plasmid propagation, the E. coli transfer strain Top 10 (Invitrogen) [F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 recA1 araD139 Δ(ara leu)7697 galU galK rpsL(StrR) endA1 nupG] was used.
[0083] Recombinant expression was carried out in strain BL21(DE3)[F-ompT hsdSB(rB-mB)gal dcm(DE3)] (NEB).
[0084] The shuttle plasmid pUC57 (Genscript) containing the hybrid sequence and the expression plasmid pET26a were digested with NcoI and XhoI. After electrophoresis, the insert and linearized pET26a bands were recovered by gel extraction (QIAGEN). The gel purified insert was ligated into pET26a at an insert to plasmid ratio of 3. The ligation reaction was used to transform chemically competent E. coli Top 10 and plated on LB agar containing 50 μg / mL kanamycin in Petri dishes.
[0085] Six bacterial colonies were picked in liquid medium containing kanamycin for plasmid minipreparation on silica columns (QIAGEN). Correct insertion of the insert into pET26a was checked by digestion with informative restriction enzymes (Figure 2).
[0086] Plasmids with the correct restriction profile were selected and used to transform BL21(DE3) bacteria.
[0087] Transformation with the correct plasmid was confirmed in six BL21(DE3) clones analyzed by restriction enzyme digestion as described above.
[0088] Optimizing recombinant protein production in small-volume bacterial cultures Parameters such as duration of recombinant protein production, inducer (IPTG) concentration and temperature were analyzed in small scale cultures (1L) in Erlenmeyer flasks. 5ml of steady state overnight culture was diluted into 1L (1:200) and further grown at 30°C to an optical density at 600nm of 0.7-0.8. Induction of recombinant protein expression was assayed at three temperatures, 22, 30 and 37°C, using two IPTG inducer concentrations, 0.1 and 1mM. The best recombinant yield was obtained after overnight culture at 22°C and induction with 0.1mM IPTG.
[0089] After purification by immobilized metal affinity chromatography (IMAC), yields of 1-2 mg of recombinant product were obtained per liter of bacterial culture.
[0090] Production and purification of PP21 Laboratory-scale (1-2 liter) production was performed to obtain sufficient PP21 recombinant protein to perform preclinical immunogenicity studies in mouse and primate models.
[0091] Protocols for bacterial culture and recombinant protein production have been previously established for small scale cultures.
[0092] The C-terminal hexahistidine-tagged recombinant protein PP21 was purified by affinity chromatography with Ni-NTA resin (QIAGEN).
[0093] Two purification procedures were investigated, under native or denaturing conditions.
[0094] Indeed, under native conditions, no recombinant protein was found in the insoluble fraction of bacterial lysates, but purification under denaturing conditions was also assayed, with immobilized Ni on Ni-NTA resin. 2+ For metals, the impact of putative conformational effects of the three-dimensional structure of PP21 on the availability of the histidine tag was evaluated.
[0095] Purification under native conditions - Bacterial cells were harvested by centrifugation (4000g, 30 min, 4°C). - The bacterial pellet was suspended in 5 mL of lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) per gram of biomass. -Lysates were shaken with 1 mg / mL lysozyme on ice for 30 min. - Bacteria were lysed using a 530 second burst of 150W with a 30 second cooling interval. -Lysates were shaken for 30 min on ice with 5 μg / mL DNAse I and 10 μg / mL RNAse A supplemented with a set of protease inhibitors (Roche). Lysates were clarified by centrifugation at -10000g for 30 min at 4°C. - The lysate was filtered through a 0.22 μm sieve and incubated overnight with 200 μL of NiNTA resin in a volume of 20 mL on a rocking tray at 4°C. - The resin was washed thoroughly 5 times with a volume of 40 mL of lysis buffer. An aliquot of the first stage supernatant (lysate after resin incubation) was saved for analysis. The centrifugation step was no longer than 5 min at 200 g. Recombinant protein was recovered by incubating the resin in 500 μL of lysis buffer containing 5× 250 mM imidazole. -Elution fractions were pooled and dialysed against PBS pH 7.3 by ultrafiltration through a 30 kDa sieve.
[0096] Protein concentrations were measured spectrophotometrically at 280 nM and further characterized by electrophoresis (SDS-PAGE 10%) and immunoblotting as shown in FIG. 3 for PP21.
[0097] Purification under denaturing conditions Bacterial cells were harvested by centrifugation (4000 g, 30 min, 4° C.). The bacterial pellet was suspended in 5 mL of modified lysis buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, NaOH pH 8.0) per gram of biomass. The lysate was shaken on ice for 30 min. Bacteria were further lysed with a 530 second burst at 150 W with a 30 second cooling interval. Lysates were clarified by centrifugation at 10000g for 30 min at 4°C. The lysate was filtered through a 0.22 μm sieve and incubated overnight with 200 μL of NiNTA resin in a volume of 20 mL on a rocking tray at 4°C. The resin was washed extensively 5 times with a volume of 40 mL of denaturing lysis buffer. An aliquot of the first stage supernatant (lysate after resin incubation) was saved for analysis. The centrifugation step was at 200 g for 5 min or less. Recombinant protein was recovered by incubating the resin in 500 μL of lysis buffer containing 5 times 250 mM imidazole. The eluted fractions were pooled and dialysed against PBS pH 7.3 by ultrafiltration through a 30 kDa sieve.
[0098] The purification yields by the two methods were similar, suggesting that the affinity histidine tag is functional in the native form of PP21.
[0099] In over 10 production / purification experiments at 1 liter scale in Erlenmeyer flasks, purified yields of 0.7-1 mg of recombinant protein PP21 per liter of bacterial culture were reproducibly obtained.
[0100] FIG. 3 shows the recombinant protein PP21 purified by IMAC.
[0101] Temperature stability of PP21 The stability of PP21 as a function of storage temperature, assessed by Western blotting, is shown in Figure 4. After a storage period of 21 days in a refrigerator at 6 °C, no signs of degradation were observed. At room temperature, PP21 started to show signs of degradation in the same period, whereas at 37 °C it was completely degraded after 8 days. However, this instability cannot be attributed to a putative endogenous molecular instability, since it is not a GMP manufactured product and may contain traces of proteases.
[0102] The amino acid sequence of the recombinant protein expressed in E. coli by pET26a is shown below, with the sequence in brackets coming from the expression plasmid and the bolded sequence coming from the CRM197 diphtheria toxin.
[0103] The C-terminal hexahistidine tag used for purification by immobilized metal affinity chromatography (IMAC) is underlined.
[0104] Sequence of PP21 MSP3-1 (italic underlined) (PlasmodB ID: PF3D7_1035400), residues 155 to 249 (95 aa) [ka] PP22; sequence of MSP3-2 (italic underlined) (PlasmodB ID: PF3D7_1035500), residues 178 to 257 (79 aa) [ka] PP23; sequences of MSP3-2 (italic underline before CRM197) (PlasmodB ID: PF3D7_1035500), residues 178-257 (79 aa) and MSP3-3 (italic after CRM197) (PlasmodB acc.Nbr PF3D7_1035600), residues 246-307 (61 aa) [ka] PP25; sequence of LSA-3 (italic underlined) (PlasmodB ID: PF3D7_0220000), residues 176 to 325 (150 aa) [ka] LSA5-CRM protein sequence (SEQ ID NO:89) [ka]
[0105] Human Immunogenic Mouse Model (HIMM): This model is based on the transplantation of human splenic lymphocytes (Hu-SPL-NSG) into immunodeficient NOD-SCID-IL-2rγ null (NSG) mice and complements the information obtained using conventional laboratory mice, e.g. Balb / C and C57BL.
[0106] Immunization of Balb / c or C57Bl / 6 mice and blood sampling Groups of 4-5 Balb / c or C57Bl / 6 mice received 2 or 3 injections of 10 μg MSP3-1-LSP or 1 μg PP21 diluted in 100 μl phosphate buffered saline pH 7.2 (PBS) and emulsified with 100 μl of the adjuvant Montanide ISA 720. Immunizations were performed by subcutaneous injection and were repeated once or twice 15 days apart. Blood collections were performed by tail bleeding starting 2 weeks after the second injection and were repeated at 15-day intervals until 160 days after the first antigen injection. Serum was separated and stored at -20°C until use. Other groups treated in parallel received either 1 μg or 0.2 μg PP21.
[0107] Determination of anti-MSP3-LSP antibody titers in mouse sera MSP3-LSP-specific antibody titers were determined in mouse sera by enzyme-linked immunosorbent assay (ELISA). Flat-bottom microtitration plates (Nunc-Thermo Scientific, USA) were coated overnight at 4°C with 2 μg / ml MSP3-1-LSP or one of the MSP3-1-LSP peptides a, b, c or d diluted in PBS. After washing (PBS, pH 7.2) and saturation (PBS, 3% skim milk), serial dilutions of test sera (diluted in PBS, 3% skim milk, 0.05% Tween 20) were added and incubated for 1 h. Negative controls consisted of pre-immune mouse sera. Specific antibodies were then revealed by adding horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) (Invitrogen, USA) for 1 h, followed by the addition of the peroxidase substrate tetramethylbenzidine (Amresco, USA). The specific antibody titer corresponds to the reciprocal of the last positive dilution.
[0108] Human spleen donation and ethical guidelines Human spleens were obtained from deceased organ transplant donors according to an ethical agreement with the National Organization for Organ & Tissues Donation & Transplantation (NOOTDT) of Lebanon, where the patients themselves, or their parents after their death, signed informed consent for organ donation for transplantation or scientific research.
[0109] Human spleen cell preparation Human spleens were processed within 24 hours after surgical resection as previously described (Brams P, 1998). Briefly, spleen tissues were dissected and cell suspensions were prepared. Gey's solution was used to lyse red blood cells for 5-10 min at 25°C. After washing, leukocytes were resuspended in a medium consisting of 37% fetal calf serum (FCS) (Sigma, USA), 10% dimethyl sulfoxide (DMSO) (Sigma, USA) and 53% RPMI1640 (Sigma, USA) and then frozen and stored in liquid nitrogen until use. The average number of cells isolated from each spleen donor was 100 ± 4 billion.
[0110] Engraftment and immunization of human spleen cells in NSG mice NOD.Cg-Prkdcscid-IL2rγtm1WjI / SzJ (NSG) mice were obtained from The Jackson Laboratories (USA) and housed in sterile microisolators. Food, water, cages, and bedding were all autoclaved before use. 6-8 week-old NSG mice were admitted to the experiment.
[0111] On day 0, human spleen cells were cultured at 4 × 10 cells in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% non-essential amino acids (NEAA 100x), 2 mM glutamine, 2 mM sodium pyruvate, and 50 μg / ml gentamicin (complete medium) with or without 1 μg / ml antigen. 6All culture reagents were purchased from Sigma, USA. Recombinant human IL-2 (Gibco Invitrogen) was added at 25 IU / ml on day 1. On day 3, spleen cells were harvested, washed, and resuspended in Hank's balanced salt solution (HBSS). Each NSG mouse received 30 × 10 antigen-primed or non-primed spleen cells. 6 Reconstituted mice (Hu-SPL-NSG) received 10 μg of antigen intraperitoneally (i.p.) in 200 μl of HBSS-Montanide ISA 720 or MF59 adjuvant (v / v) on days 7 and 21. Mice reconstituted with non-primed splenocytes received adjuvant alone. Blood samples were collected one week after each boost.
[0112] Determination of human MSP3-1-LSP-specific antibodies in Hu-SPL-NSG mouse serum These determinations were performed by ELISA. Briefly, for detection of total human IgG in mouse serum, flat-bottom microtitration plates (Nunc-Thermo Scientific, USA) were coated overnight at 4°C with 2.5 μg / ml purified goat anti-human IgG (H+L) (Invitrogen, USA) in 0.1 M carbonate buffer, pH 9.5. After washing (PBS, pH 7.2) and saturation (PBS, 3% skim milk), test serum (diluted in PBS, 3% skim milk, 0.05% Tween 20) was added and incubated for 1 h. Negative controls consisted of pre-immune mouse serum from the same animals. Human IgG was subsequently revealed by adding horseradish peroxidase-conjugated goat anti-human IgG (H+L) (Invitrogen, USA) for 1 h, followed by the addition of the peroxidase substrate tetramethylbenzidine (Amresco, USA). Total human IgG concentrations were calculated in Hu-SPL-NSG mouse serum by comparison with a standard human IgG solution (Zymed, USA). The same test was performed for the detection of antigen-specific antibodies, except that the plates were coated with 2.5 μg / ml MSP3-1-LSP in PBS. In this case, the negative control consisted of serum from individuals never infected with Plasmodium, and the positive control consisted of a pool of sera from hyperimmune African adults. In both cases, serial dilutions of each serum were tested to determine the antibody titer. For the specific antibody titer determination, the test was considered positive if an absorbance above the cutoff (negative control OD × 2) was obtained. Detection of IgG subclasses was performed using secondary mouse monoclonal antibodies specific for human IgG subclasses (clones NL16 [IgG1; Skybio, UK], HP6002 [IgG2; Sigma-Aldrich, Germany] and Zg4 and GB7B [IgG3 and IgG4, respectively; Skybio, UK) were used at final dilutions of 1 / 4,000, 1 / 10,000, 1 / 10,000 and 1 / 60,000, respectively), followed by horseradish peroxidase-conjugated goat anti-mouse IgG (Invitrogen) diluted 1 / 4000 in PBS.
[0113] Quantification of gene expression of different cytokines, chemokines and transcription factors by real-time reverse transcription PCR (RTqPCR) Spleen cells from immunized and non-immunized mice were cultured at 2 × 10 cells in complete RPMI 1640 medium with or without stimulation with the immunizing antigen. 6After 24 h of incubation, total cellular RNA was extracted using the RNeasy Mini Kit (Quiagen, Germany). Reverse transcription was performed using RevertAid M-MuLV enzyme (RevertAid kit First Strand Synthesis kit, Thermo Scientific Fermentas) in a 20 μl reaction mixture. Briefly, 1 μl of oligo dT18 primer was added to approximately 400 ng of total RNA, mixed and incubated at 65°C for 5 min. As recommended by the manufacturer, the tube was placed on ice for a few minutes and briefly centrifuged before adding 5x reaction buffer, Ribolock Rnase inhibitor (20 u / μl), dNTPs (10 mM) and reverse transcriptase (200 u / μl). The reaction mixture was incubated at 42°C for 60 min. The enzyme was inactivated by heating at 70°C for 5 min. Quantitative PCR was used to measure the relative expression of different human cytokines, chemokines and transcription factors considered characteristic of Th1 or Treg cells. PCR mixtures were performed using a LightCycler 480 SYBR Green Master, La Roche, as recommended by the manufacturer. PCR amplification was performed in a LightCycler 480 machine (La Roche) at 95°C for 5 min (1 cycle), followed by 45 cycles of incubation at 95°C for 10 s and 55-57°C for 10 s. Each sample was run in triplicate. Housekeeping genes used as internal standards were beta-actin (β-actin) and hypoxanthine phosphoribosyltransferase 1 (HPRT1) (geNorm analysis). Cycle threshold values (Ct) were calculated based on the generated PCR curves. Relative expression was calculated by the 2ΔΔCt method.
[0114] Immunofluorescence assay. Immunofluorescence assays were performed using air-dried acetone-fixed thin smears from erythroid cultures containing mainly mature schizonts of P. falciparum (3D7). Hu-SPL-NSG serum diluted in PBS-1% bovine serum albumin was incubated for 1 h at 37°C in a humidified chamber. After washing with PBS, antibodies were detected by using AlexaFluor-conjugated goat anti-mouse IgG (Molecular Probes and Invitrogen) diluted 1 / 400 in PBS with Evans blue counterstain (1 / 200).
[0115] result Example 1: Immunogenicity of PP21 (CRMP97-MS3 fusion construct) The following animal models: BALB-C mice C57BL mice Saimiri sciureus monkey Human Immunogenic Mouse Model (HIMM) In this study, the immune response induced by PP21 was evaluated (immunodeficient NSG mice were immunized in vivo with cells from human spleen tissue transplanted into the mice, and serum and cells from the immunized animals were used in immune assays).
[0116] Since laboratory mice usually respond poorly to alum, since alum is not available by injection route in HIMM, and above all, since we know that in humans alum-adjuvanted CRM (in meningococcal or pneumococcal vaccines) as MSP3 LSP provides very good responses, and since we aimed to compare constructs and not adjuvants, we performed all experiments using Montanide ISA 720 in comparison with the benchmark antigen MSP3-LSP (a long synthetic peptide covering the 186-271 region of MSP3-1) used in clinical experiments.
[0117] Nevertheless, successful immunization with alum was also performed in laboratory mice, yielding titers of >25600 even after two immunizations in Balb / C and titers of 3200-25600 in C57bl (Figure 19).
[0118] A significant improvement in immunogenicity was observed when using the PP21-bio fusion MSP3-1 construct of the present invention in mice, compared to MSP3-LSP. In all models used, PP21 induces a higher target cell affinity subclass of serological response than the benchmark antigen MSP3-LSP.
[0119] 1. Low doses are very efficient: As with other CRM conjugate vaccines, a large increase in immunogenicity was obtained, indicating that the fusion procedure produced a product as efficiently as chemical conjugation. We immediately used very low doses to compare only 1 μg of PP21 with 10 μg of the reference MSP3-LSP (previously, in laboratory mice, 10 μg was found to be not significantly different from the 15 μg used in the clinic). These differences were determined by different means. See Figures 6-9. The results were reproducible with four distinct batches of PP21 in four groups of Balb / C and C57bl mice. Furthermore, we investigated PP21 dosing in mice and squirrel monkeys, focusing on lower doses, e.g. 0.2 μg compared to 1 μg. Because of the high immunogenicity, we also investigated only two immunizations compared to three immunizations.
[0120] 2. Broader recognition of ADCI targets: Peptides "b", "c" and "d" included in the vaccine construct define distinct B cell epitopes targeted by antibodies effective in ADCI. As shown in Figure 9, sera from mice vaccinated with PP21 (right panel) showed higher reactivity with these peptides at 1 and 10 μg, respectively, compared to the current MSP3-1-LSP (left panel), suggesting that PP21 has a higher and broader scale and scope of recognition of ADCI targets. Consistent with this finding, PP21 had a broader recognition pattern of six MSP3 family members that showed cross-reactivity mainly via peptides ≪b≫ and ≪cd≫. This also means that antibodies elicited by PP21 trigger ADCI via antibody cross-linking triggering to six proteins on the merozoite surface, not just one.
[0121] 3. Highly advanced B cell responses in human lymphocytes: More importantly, human B cell responses evaluated in the HIMM model showed similarly large improvements, with a 40-100 fold increase in immunogenicity (Figure 10). In parallel experiments, using PP21 versus the current 96 amino acid MSP3-LSP, antibody titers were 20-100 fold higher with 1 μg PP21 than with 10 μg MSP3-LSP. Results were reproducible in three groups of five animals belonging to the three HLA classes.
[0122] 4. Results are reproducible when using either Montanide ISA720 or MF59 as adjuvant (Figure 14).
[0123] 5. In vitro challenge of human lymphocytes with the parasite component MSP3-LSP resulted in high IFN-γ secretion (Figure 11). This important result indicates that the CRM Th epitope did not neutralize the plasmodium-specific MSR3 T cell epitope, and therefore T cell help can be expected from vaccinated individuals upon parasite challenge, increasing the likelihood of a rapid anamnestic antibody rise if needed.
[0124] Detailed analysis of the cytokine profile shows that responding cells are predominantly of the T helper 1 type (FIG. 12 shows examples of results obtained with CXCL10 and Tbet).
[0125] 6. Dominance of cytophilic IgG1: Isotype studies revealed a strong dominance of the cytophilic isotype, composed almost entirely of IgG1, which was also the dominant isotype in MSP3-LSP immunized individuals, as expected for a strong Th1 response. This was true when either Montanide or MF59 was used as adjuvant (Figures 15 and 16). Although these results were obtained in a human model, they are highly representative of future responses that may be elicited in volunteers.
[0126] 7. Reactivity with native parasite proteins: In IFAT (Figure 13) and Western blot, antibodies induced by PP21 vaccination reacted with parasite native proteins. Antibody reactivity with parasite proteins, and above all with synthetic antigens, is a key feature for activating ADCI protective mechanisms during a malaria attack and for adequate augmentation of antibody responses by natural parasite challenge.
[0127] 8. Very low immunization doses are efficient: For MSP3-LSP, 0.2 μg and 1 μg per immunization were evaluated compared to 10 μg (Figure 17). At the 1 μg PP21 dose, a plateau was reached after the second immunization, whereas at the 0.2 μg dose, a third immunization was required to reach nearly the same high antibody levels, and one animal did not respond. Nevertheless, the 1 μg profile indicates that two immunizations may be sufficient and therefore worthy of validation.
[0128] 9. Similar high immunogenicity is observed in South American Saimiri sciureus monkeys (Figure 20): PP21 1 μg and 0.2 μg adjuvanted with Montanide 720 was used to immunize South American primates, which normally respond poorly to immunization. At 1 μg, high responses were achieved, approaching the titers seen in mice (see Figure 18), and at 0.2 μg, titers were about 5-fold lower (not shown). Our Brazilian colleagues have not yet performed a comparison of titers in the same experiment, but the MSP3 LSP was very poorly immunogenic when used in this model.
[0129] 10. Duration of immune response is significantly improved (Figure 8 upper and lower panels): Long-term analysis showed significant improvement of essential components; Duration of antibody response: Mice immunized with PP21 or LSP were followed for 6 months after immunization. There is a gradual but slow decline in titers such that at the 6 month time point, the remaining titers are higher than the peak obtained using MSP3-LSP. Titers were still in the range of 1 / 200000-1 / 300000 for PP21 over 6 months compared to approximately 1 / 50000 range for the current MSP3-LSP.
[0130] Example 2: Immunogenicity of PP25 (CRMP97-LSA3 fusion construct) LSA3 is a pre-erythrocytic antigen with many attractive features, discovered by contrasting differential responses of protected and non-protected volunteers, is highly antigenic and immunogenic in a wide range of animals, including higher primates and chimpanzees, in the latter case inducing a protective immune response against massive challenge with the human sporozoite stage of the parasite Plasmodium falciparum. Protection is associated with an antigen-specific interferon gamma response. The immunogenicity of PP25 was compared to a control construct using LSA3 (DG729) without conjugation or any fusion. The conditions of immunization and immunoassay were identical to those described above for PP21.
[0131] Even when low doses of antigen were used, a similar large increase in antibody response was observed with the LSA3-CRM97 biofusion as with MSP3 in PP21. Because uncarried LSA3 (DG729) is already a very good inducer of IFN-g responses, an increase in IFN-g responses was also observed, but was less pronounced.
[0132] The increases recorded in balb / C and C57bl mice were also confirmed in human immunogenicity models.
[0133] The inventors further demonstrated a very strong correlation between anti-LSA3 antibody titers and inhibition of the sporozoite stage of P. falciparum parasites.
[0134] See the results shown in Figures 21-26.
[0135] Example 3: Immunogenicity of PP23 (MSP3-2-CRMP97-MSP3-3 fusion construct) The results obtained with PP21, which relies on the fusion of MSP3-1 with CRM and LSA3, proved to be reproducible using other antigens derived from the erythrocytic stage, such as MSP3-2 and MSP3-3, in a construct carrying CRM (designated PP23). Indeed, in human lymphocytes transplanted in a HIMM model, construct PP23 (MSP3-2-CRMP97-MSP3-3) induced strong B- and T-cell responses (Figure 27), with titers on average 10-fold higher than in mice immunized with MSP3-2 CT alone in Montanide. The antibody subclasses were dominated by the IgG1 class, the main cell affinity class capable of acting in concert with monocytes in the ADCI mechanism. Similarly strong T-cell responses were induced, as measured by IFN-γ secretion by PP23-immunized human lymphocytes restimulated in vitro with either MSP3-2 or MSP3-3.
[0136] Example 4: LSA5-CRM Liver stage antigen-5 (LSA-5), also known as PEBS (pre-erythrocytic and blood stage antigen) or SR 11.1 (a subregion of the 11.1 P. falciparum gene), combines features of both MSP3 and LSA3 in a single molecule. It contains a unique sequence that distinguishes it from the rest of the megagene Pf 11.1 and is completely conserved across lineages. It is unique in that it was recognized by sera from volunteers immunized with radiation attenuated sporozoites, as it induces protection against both pre-erythrocytic and asexual blood stages. It is expressed in both pre-erythrocytic and blood stages. The protective role of LSA5 against pre-erythrocytic stages is supported by convergent in vitro invasion inhibition studies, in vivo protection by passive transfer of anti-LSA5 antibodies, and by proof-of-concept studies in primates protected from challenge by vaccination with recombinant LSA5. Both naturally occurring human anti-Pf LSA5 antibodies and artificially induced animal anti-Pf LSA5 antibodies exert parasite-killing ADCI-mediated effects against blood stages. In individuals from endemic areas, IgG3 antibodies predominate in individuals with high antigenicity and correlated immunity (i.e., exposure-induced protection). Numerous epidemiological studies have found a strong association between protection against clinical malaria attacks and improved prognosis in drug-treated cerebral malaria. Finally, LSA5 is highly immunogenic, achieving significantly higher titers in mice and higher ADCI activity than sera from MSP3-immunized mice.
[0137] The biofusion of LSA5 with CRM197 (the principle of which is similar to the previous three examples) was expressed in E. coli to confirm its antigenicity and to carry out preliminary immunogenicity studies. When the fusion with CRM was used, LSA5 immunogenicity was very high (Figure 28); the immunogenicity of the biofusion LSA5-CRM / Montanide ISA720 at a dose of 10 μg and 1 μg was compared in BALb / c mice (n=5). The experimental conditions were similar to those with MSP3 described in Figure 8. Immunization with biofusion LSA5-CRM / Montanide ISA 720 was carried out on days 0, 14 and 28 (arrows). Serum antibody detection was carried out by ELISA titration against LSA5-LSP as antigen using sera collected on days 0, 7, 21 and 42.
Claims
1. A fusion protein comprising at least one antigenic sequence fused to the N-terminus and / or C-terminus of a carrier heterologous toxoid protein sequence, the antigenic sequence comprises an epitope sequence of a Plasmodium protein having a length of at least 5 amino acids, the carrier heterologous toxoid protein sequence is a sequence that is highly immunogenic in humans; The fusion protein is encoded by a single nucleic acid and the sequence of the carrier heterologous toxoid protein is directly linked to the antigenic sequence without chemical coupling; The sequence of the fusion protein comprises a Plasmodium protein fused to a carrier protein, CRM197 or a toxoid protein containing an epitope sequence of at least 5 amino acids in length of a tetanus toxoid protein, the Plasmodium protein containing an epitope sequence of at least 5 amino acids in length of any of the MSP3, LSA3 or LSA5 proteins, The fusion protein includes any of the following fusion constructs: CRM197-MSP3-1, CRM197-LSA3, MSP3-2-CRM197-MSP3-3, LSA5-CRM197, tetanus toxoid-MSP3-1, tetanus toxoid-LSA3, MSP3-2-tetanus toxoid-MSP3-3, LSA5-tetanus toxoid, or LSA5-tetanus toxoid. Fusion proteins.
2. A nucleic acid construct encoding a fusion protein as defined in claim 1.
3. A vector comprising the nucleic acid construct of claim 2 in an expression cassette.
4. A host cell into which the vector of claim 3 has been inserted.
5. An in vitro method for preparing a fusion protein as defined in claim 1, comprising allowing replication of a host cell as defined in claim 4 under conditions inducing expression of a nucleic acid construct as defined in claim 2, and collecting the fusion protein thus expressed.
6. 1. A vaccine comprising a fusion protein as defined in claim 1, or a combination of at least two fusion proteins as defined in claim 1, each comprising at least two different antigenic amino acid sequences, or a nucleic acid construct encoding said fusion protein as defined in claim 2, together with a physiologically acceptable vehicle.
7. 7. The vaccine of claim 6 for use in the vaccination of a human subject against malaria.
Citation Information
Patent Citations
An immunogen comprising a peptide and a carrier derived from protein d of h.influenzae
JP2002537354A
malaria vaccine
JP2006512926A
aβ immunogenic peptide carrier conjugate and method for producing same
JP2007534650A
Fusion proteins containing the non-toxic mutant of diphtheria toxin CRM197 or its fragments.
JP2014518061A
Immunogenic fusion polypeptide
JP2016515104A
